Gaps,Goals and Getting to Target: A Call to Action for Pharmacists!

Abstract

Get full access to this article

View all access options for this article.

References

McPherson

Frohlich

Fodor

Genest

. Canadian Cardiovascular Society position statement — recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913–27.

Heart and Stroke Foundation of Canada. Statistics. Available: www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm (accessed September 12, 2008).

Baigent

Keech

Kearney

Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.

Olson

Bungard

Tsuyuki

. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy 2001;21:807–17.

Ellis

Erikson

Stevenson

Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638–45.

Blenkinsopp

Anderson

Armstrong

. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med 2003;25:144–53.

Pearson

Thompson

Semchuk

. Guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. Can Pharm J 2008;141[Suppl 2]:S11–6.